Biotech firm Dendreon is set to begin selling its prostate cancer vaccine "Provenge" in Europe. John Johnson, Dendreon chairman & CEO, discusses the European launch and addresses investor concerns.» Read More
Last year $2 billion worth of products were sold with a label saying they do not contain ingredients from genetically modified organisms, but the claim wasn't backed by regulators.
Biotech and drug companies say the benefits of genome research are on the way, and just as importantly, advances are pushing the technology toward affordability.
Russian tycoon Dmitry Itskov is convening a meeting of the minds to explore the possibility of creating lifelike copies of humans, something he thinks is possible by 2035.
A strain of genetically engineered wheat never approved for sale or consumption was sprouting on a farm in Oregon, the Agriculture Department said Wednesday.
Shares of Pandora are up after the company reported earnings, reports CNBC's Seema Mody. And there are reports a deal between Valeant Pharmaceuticals and Bausch & Lomb could be completed as early as next week.
Following is Cramer's homework. And he's concerned about a few of the stocks he's just researched.
Amgen's stock fell sharply in after-hours trading after it reported sales that fell short of Wall Street's expectations.
Mark Lehmann, JMP Securities president, provides investment strategies that include a biotech company with a promising drug to fight a rare form of Leukemia.
Road trip! Road trip! In the second stop, CNBC's Brian Sullivan reports on the biotech boom in San Diego.
San Diego Mayor Bob Filner (D) discusses the growing sectors in the city, rising home prices, and the burgeoning biotech industry.
CNBC's Jane Wells reports on business in San Diego, how the city has come back from the brink of bankruptcy, and the diversity of the economy. Just the same, taxes are among the highest in the country.
San Diego has the 2nd largest biotech industry in the U.S. CNBC's Brian Sullivan is there to check it out.
Biotech has returned 20 percent for investors this year. Biogen IDEC CEO George Scangos, discusses the recent FDA approval of his company's drug, which is its first pill for multiple sclerosis.
It is the 95th consecutive trading session in which Apple shares trade below its 50-day moving average, reports CNBC's Seema Mody.
CNBC's Seema Mody reports BlackBerry is up today after reports that BBerry 10 is selling faster than expected.
An internal analysis conducted by Johnson & Johnson in 2011 estimated that the all-metal device would fail within five years in nearly 40 percent of patients who received it, newly disclosed court records show.
Biotech stocks are outperforming the major indices, and are up 3 percent over the past week. CNBC's Seema Mody is tracking which stocks are trending on Twitter.
Eli Lilly will be "very challenged" by the loss of exclusivity on several blockbuster drugs, CEO John Lechleiter told CNBC on Tuesday, but added the company can manage its growth in response.
Charles River Laboratories CEO James Foster discusses competition in the drug market, drug patents and where his business is headed in 2013.
Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.